Theophyllin in der Langzeittherapie der COPD - immer noch aktuell?

 

 Permissions and Reprints

Zusammenfassung

Die COPD ist im letzten Jahrzehnt in den Mittelpunkt des Interesses der Pneumologen und der klinisch-therapeutischen Forschung gerückt. Erkenntnisse über die weltweit ansteigende Morbidität und Letalität und deren sozio-ökonomische Folgen haben die Aufgabe, sich mit dieser Erkrankung zu beschäftigen, dringlicher gemacht. Neue Therapieoptionen berechtigen zu einem vorsichtigen Optimismus. Das Repertoire der Pharmakotherapie wurde um die Indikation für lang wirksame Betaadrenergika und das lang wirksame Anicholinergikum Tiotropium bereichert, inhalative Glukokortikoide gewinnen nun auch bei der COPD an Reputation. Über diesem neuen Trend scheint eine altbewährte und kostengünstige Substanz, das Theophyllin, in den Hintergrund zu geraten. Diese Übersichtsarbeit verweist auf seine gut dokumentierte Wirkung als Bronchodilatator und auf additive Effekte in Kombination mit Betaadrenergika und Anticholinergika. Weitere positive Wirkungen des Theophyllins auf Dyspnoe und Belastbarkeit, auf die Atemmuskulatur und auf Herz-Kreislauf-Funktionen werden diskutiert, jedoch besteht zur Klärung der klinischen Relevanz noch Forschungsbedarf. Bei kritischer Verordnung und Überprüfung der individuellen Reaktion bleibt Theophyllin für einen Teil der Patienten mit COPD eine wertvolle therapeutische Option.

Abstract

In the last decade the interest of pneumologists and therapeutic research has been focused on COPD. The increasing morbidity and mortality world wide and the important socio-economic impact challenged to improve the therapeutic options. New indications like LABA and newly introduced drugs like tiotropium may help to ameliorate symptoms, ICS potentially help to protect against exacerbations and to suppress components of the inflammatory process even in COPD. A reappraisal of the place of theophylline in the stepwise approach to treat these patients seems to be useful. This report reviews its effects as bronchodilator and the well documented additive effects in combination with betaadrenergics and anticholinergics. Further desirable actions of theophylline on the sensation of dyspnoea and on exercise capacity, on respiratory muscle function and on the cardiovascular performance are discussed but no definite conclusions can be made about the clinical utility of these effects. Given that patients are carefully selected in terms of benefit and side effects theophylline may remain a valuable therapeutic option.

Literatur

• 1 American Thoracic Society . Standards for the diagnosis and care of patients with Chronic Obstructive Pulmonary Disease.  Am J Respir Crit Care Med. 1995;  152 S77-S120
  PubMedGoogle Scholar
• 2 O'Byrne P M, Postma D S. The many faces of airway inflammation. Asthma and chronic obstructive pulmonary disease. Asthma Research Group.  Am J Respir Crit Care Med. 1999;  159 S41-S63
  PubMedGoogle Scholar
• 3 The World Health Report 1997 .Conquering suffering, enriching humanity. Geneva: World Health Organization 1997: 47
  Google Scholar
• 4 Murray C J, Lopez A D. Alternative projections of mortality and disability by cause 1990 - 2020: Global Burden of Disease Study.  Lancet. 1997;  349 1498-1504
  CrossrefPubMedGoogle Scholar
• 5 Konietzko N, Fabel H. Weißbuch Lunge 2000. Stuttgart-New York: Thieme
  Google Scholar
• 6 Sullivan D, Ramsey S D, Lee T A. The economic burden of COPD.  Chest. 2000;  117 (2 Suppl) 5S-9S
  CrossrefPubMedGoogle Scholar
• 7 Calverly P, Pauwels R, Vestbo J. et al . Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial.  Lancet. 2003;  361 449-456
  CrossrefPubMedGoogle Scholar
• 8 Sin D D, TU J V. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2001;  164 580-584
  CrossrefPubMedGoogle Scholar
• 9 Soriano J B, Vestbo J, Pride N B. et al . Survivial in COPD patients after regular use of fluticasone propionate and salmeterol in general practice.  Eur Respir J. 2002;  20 819-825
  CrossrefPubMedGoogle Scholar
• 10 Ram F SF, Jones P W, Castro A A. et al .Oral theophylline for chronic obstructive pulmonary disease (Cochrane Review). In: The Chochrane Library, Issue 2. Oxford: Update Software 2003
  Google Scholar
• 11 Wallack R L, Mahler D A, Reilly D. et al . Salmeterol plus theophylline combination therapy in the treatment of COPD.  Chest. 2001;  119 1661-1670
  CrossrefPubMedGoogle Scholar
• 12 Rossi A, Kristufek P, Levine B E. et al . Comparison of the efficacy, tolerability and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD.  Chest. 2002;  121 1058-1069
  CrossrefPubMedGoogle Scholar
• 13 Chrystyn H, Mulley B A, Peake M D. Dose response relation to oral theophylline in severe chronic obstructive airway disease.  BMJ. 1988;  297 1506-1510
  PubMedGoogle Scholar
• 14 Kirsten D, Wegner R E, Jörres R A. et al . Effects of theophylline withdrawal on severe chronic pulmonary disease.  Chest. 1993;  104 1101-1107
  PubMedGoogle Scholar
• 15 Filuk R B, Easton P A. Anthonisen NR. Responses to large doses of salbutamol and theophylline in patients with chronic obstructive pulmonary disease.  Am Rev Respir Dis. 1985;  132 871-874
  PubMedGoogle Scholar
• 16 Dullinger D, Kronenberg R, Niewoehner D E. Efficacy of inhaled metaproterenol and orally-administered theophylline in patients with chronic airflow obstruction.  Chest. 1986;  89 171-173
  PubMedGoogle Scholar
• 17 Gyatt G H, Towsend M, Keller J. et al . Measuring functional status in chronic lung disease: conclusions from a randomized trial.  Respiratory Medicine. 1989;  83 293-297
  PubMedGoogle Scholar
• 18 Thomas P, Pugsley J A, Stewart J H. Theophylline and salbutamol improve pulmonary function in patients with irreversible chronic obstructive pulmonary disease.  Chest. 1992;  101 160-165
  PubMedGoogle Scholar
• 19 Nishimura K, Koyama H, Ikeda A. et al . The additiv effect of theophylline on a high dose combination of inhaled salbutamol and ipratropium bromide in stable COPD.  Chest. 1995;  107 718-723
  PubMedGoogle Scholar
• 20 Leitch A G, Morgan A, Ellis D A. et al . Effect of oral salbutamol and slow-release aminophylline on exercise tolerance in chronic bronchitis.  Thorax. 1981;  36 787-789
  PubMedGoogle Scholar
• 21 Evans W V. Plasma theophylline concentration, six minute walking distance, and breathlesness in patients with chronic airflow obstruction.  BMJ (Clin Res Ed). 1984;  289 1649-1651
  PubMedGoogle Scholar
• 22 Shivaram U, Cash M E, Mateo F. et al. Effects of high-dose ipratropim bromide and oral aminophylline on spirometry and exercise tolerance in COPD.  Respir Med. 1979;  91 327-334
  PubMedGoogle Scholar
• 23 Fink G, Kaye C, Sulkes J. et al . Effect of theophylline on exercise performance in patients with severe chronic obstructive pulmonary disease.  Thorax. 1994;  49 332-334
  PubMedGoogle Scholar
• 24 Mahler D A, Matthay R A, Snyder P E. et al . Sustained release theophylline reduces dyspnoea in non-reversible obstructive airway disease.  Am Rev Resp disease. 1985;  131 22-25
  PubMedGoogle Scholar
• 25 Eaton M L, MacDonald F M, Church T R. et al . Effects of theophylline on breathlesness and exercise tolerance in patients with chronic airflow obstruction.  Chest. 1982;  82 538-542
  PubMedGoogle Scholar
• 26 Tsukino M, Nishimura K, Ikeda A. et al . Effects of theophyliine and ipratropium bromide on exercise performance in patients with stable chronic pulmonary disease.  Thorax. 1998;  53 269-273
  PubMedGoogle Scholar
• 27 Liesker J W, Wijkstra P J, Ten Hacken N HT. et al . A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD.  Chest. 2002;  121 597-608
  CrossrefPubMedGoogle Scholar
• 28 Iravani J, Melville G N. Theophylline and mucociliary function.  Chest. 1987;  92 38S-43S
  PubMedGoogle Scholar
• 29 Welsh M J, Widdicombe J H, Nadel J A. Fluid transport across the canine tracheal epithelium.  J Appl Physiol. 1989;  49 905-909
  PubMedGoogle Scholar
• 30 Matthys H, Vastag E, Daikeler G. et al . The influence of aminophylline and pindolol on the mucociliary clearance in patients with chronic bronchitis.  Br J Clin Pract. 1983;  23S 10-15
  PubMedGoogle Scholar
• 31 Sutton P P, Pavia D, Bateman J RM. et al . The effect of oral aminophylline on lung mucociliary clearance in man.  Chest. 1981;  80S 889-892
  PubMedGoogle Scholar
• 32 Sigrist S, Thomas D, Howell S. et al . The effect of aminophylline on inspriratory muscle contractility.  Am Rev Respir Dis. 1982;  126 46-50
  PubMedGoogle Scholar
• 33 Vires N, Aubier M, Murciano D. et al . Effects of aminophylline on inspiratory muscle contractility.  Am Rev Respir Dis. 1984;  129 396-402
  PubMedGoogle Scholar
• 34 Aubier M, de Troyer A, Sampson M. et al . Aminophylline improves diaphragm contractility.  N Engl J Med. 1981;  305 249-252
  PubMedGoogle Scholar
• 35 Belman M J, Sieck G C, Mazar A. Aminophylline and its influence on ventilatory endurance in humans.  Am Rev Respir Dis. 1985;  131 226-229
  PubMedGoogle Scholar
• 36 Murciano D, Auclair M-H, Pariente R. et al . A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease.  N Engl J Med. 1989;  320 1521-1525
  PubMedGoogle Scholar
• 37 Foxworth J W, Reisz G R, Knudson S M. et al . Theophylline and diaphagmatic contractility.  Am Rev Respir Dis. 1988;  138 1532-1534
  PubMedGoogle Scholar
• 38 Kongragunta V R, Druz W S, Sharp J T. Dyspnoe and diaphragmatic fatigue in patients with obstructive pulmonary disease.  Am Rev Respir Dis. 1988;  137 662-667
  PubMedGoogle Scholar
• 39 Matthay R A, Berger H J, Loke J. et al . Improvement in cardiac performance by oral long-acting theophylline in chronic obstructive pulmonary disease.  Am Heart J. 1982;  104 1022-1026
  CrossrefPubMedGoogle Scholar
• 40 Parker J O, Kelkar K, West R O. Hemodynamic effects of aminophylline in cor pulmonale.  Circulation. 1966;  33 17-25
  PubMedGoogle Scholar
• 41 Berry R B, Desa M M, Branum J P. et al . Effefct of theophylline on sleep and sleep-disordered breathing in patients with chronic obstructive pulmonary disease.  Am Rev Respir Dis. 1991;  143 245-250
  PubMedGoogle Scholar
• 42 Man G CW, Chapman K R, Ali S H. et al . Sleep quality and nocturnal respiratory function with once-daily theophylline (Uniphyl) and inhaled salbutamol in patients with COPD.  Chest. 1996;  110 648-653
  CrossrefPubMedGoogle Scholar
• 43 Rühle K H. Wirkungen von Methylxanthinen, insbesondere Theophyllin, auf Schlaf, Tagesschläfrigkeit und Aufmerksamkeitskomponenten.  Atemw.-Lungenkrkh. 2002;  28 71-77
  PubMedGoogle Scholar
• 44 Culpitt S V, de Matos C, Russell R E. et al . Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in COPD.  Am J Respir Crit Care Med. 2002;  165 1371-1376
  CrossrefPubMedGoogle Scholar
• 45 Barnes P J. Theophylline: New perspectives for an old drug.  Am J Resp Crit Care Med.. 2003;  167 813-818
  CrossrefPubMedGoogle Scholar
• 46 Gyatt G H, Townsend M, Pugsley O. et al . Bronchodilators in chronic air-flow limitation.  Am Rev Respir Dis. 1987;  135 1069-1074
  PubMedGoogle Scholar
• 47 Williamson B H, Milligan C, Griffiths K. et al . An assessment of major and minor side effects of theophylline.  Aus NZ Med. 1988;  19 539
  PubMedGoogle Scholar
• 48 Hendeles L M, Weinberger M, Johnson G. Monitoring serum theophylline levels.  Clin Pharmacocinet. 1978;  3 294-312
  PubMedGoogle Scholar
• 49 Newman D, Tamir J, Speedy L. et al . Phyiological and neuropsychological effects of theophylline in chronic pulmonary disease.  Isr J Med Sci. 1994;  30 811-816
  PubMedGoogle Scholar
• 50 Aamodt T, Dahle R, Hroggen O. Effects of withdrawal of sustained-release theophylline in patients with chronic obstructive lung disease.  Allergy. 1988;  43 411-414
  PubMedGoogle Scholar
• 51 Pauwels R A, Buist A S, Calverly P MA. et al . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2001;  163 1256-1276
  CrossrefPubMedGoogle Scholar
• 52 Worth H, Buhl R, Cegla U. et al . Leitlinie der Deutschen Gesellschaft für Pneumologie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem.  Pneumologie. 2002;  56 704-738
  Article in Thieme ConnectPubMedGoogle Scholar

Prof. Dr. med. Ralf Wettengel

Schillbachstraße 13

07743 Jena